Trademark: 87827723
Word
DERADEX
Status
Registered
Status Code
700
Status Date
Tuesday, April 23, 2019
Serial Number
87827723
Registration Number
5735100
Registration Date
Tuesday, April 23, 2019
Mark Type
4
Filing Date
Friday, March 9, 2018
Published for Opposition
Tuesday, July 24, 2018

Trademark Owner History

Classifications
5 Allergy medications; Amino acid preparations for medical purposes; Antiallergic medicines; Cardiovascular agents for medical purposes; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Dietary and nutritional supplements; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders
The wording "DERADEX" has no meaning in a foreign language.

Trademark Events
Apr 3, 2018
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Mar 13, 2018
New Application Entered
Mar 15, 2018
New Application Office Supplied Data Entered
Mar 15, 2018
Teas Change Of Correspondence Received
Apr 3, 2018
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 21, 2018
Assigned To Examiner
Jun 21, 2018
Approved For Pub - Principal Register
Jul 4, 2018
Notification Of Notice Of Publication E-Mailed
Jul 24, 2018
Published For Opposition
Jul 24, 2018
Official Gazette Publication Confirmation E-Mailed
Sep 18, 2018
Noa E-Mailed - Sou Required From Applicant
Nov 14, 2018
Teas Statement Of Use Received
Nov 14, 2018
Use Amendment Filed
Dec 1, 2018
Case Assigned To Intent To Use Paralegal
Dec 1, 2018
Statement Of Use Processing Complete
Dec 5, 2018
Su - Non-Final Action - Written
Dec 5, 2018
Non-Final Action E-Mailed
Dec 5, 2018
Notification Of Non-Final Action E-Mailed
Feb 18, 2019
Teas Response To Office Action Received
Feb 22, 2019
Assigned To Lie
Feb 25, 2019
Applicant/Correspondence Changes (Non-Responsive) Entered
Feb 25, 2019
Applicant/Correspondence Changes (Non-Responsive) Entered
Feb 25, 2019
Correspondence Received In Law Office
Feb 25, 2019
Teas/Email Correspondence Entered
Feb 25, 2019
Su - Final Refusal - Written
Feb 25, 2019
Final Refusal E-Mailed
Feb 25, 2019
Notification Of Final Refusal Emailed
Mar 1, 2019
Teas Request For Reconsideration Received
Mar 5, 2019
Correspondence Received In Law Office
Mar 5, 2019
Teas/Email Correspondence Entered
Mar 5, 2019
Action Req For Recon Denied No Appeal Filed Counted Not Mailed
Mar 5, 2019
Action For Req For Recon Denied No Appeal Filed E-Mailed
Mar 5, 2019
Notification For Req For Recon Denied No Appeal Filed
Mar 5, 2019
Teas Request For Reconsideration Received
Mar 15, 2019
Correspondence Received In Law Office
Mar 15, 2019
Teas/Email Correspondence Entered
Mar 19, 2019
Allowed Principal Register - Sou Accepted
Mar 20, 2019
Notice Of Acceptance Of Statement Of Use E-Mailed
Apr 23, 2019
Registered-Principal Register
Mar 8, 2020
Teas Change Of Correspondence Received
Aug 7, 2019
Automatic Update Of Assignment Of Ownership
Mar 8, 2020
Teas Change Of Owner Address Received
Mar 8, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Mar 8, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Mar 8, 2020
Teas Change Of Domestic Representatives Address
Mar 8, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
May 13, 2020
Case Assigned To Post Registration Paralegal
Jun 11, 2020
Review Of Correspondence Complete - Information Made Of Record
Apr 23, 2024
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed

Trademark Alertz updated from USPTO on 2030-01-24